U. Berger

发表

Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up

H. Höfler, N. Harbeck, P. Dettmar, 1999, British Journal of Cancer.

Clinical Relevance of T1-S, an Oncogene-Inducible, Secreted Glycoprotein of the Immunoglobulin Superfamily, in Node-Negative Breast Cancer

H. Höfler, N. Harbeck, A. Werenskiold, 2001, Laboratory Investigation.

Impact of cumulative body mass index and cardiometabolic diseases on survival among patients with colorectal and breast cancer: a multi-centre cohort study

M. Schulze, V. Viallon, A. Tjønneland, 2022, BMC Cancer.

Long-Term Follow-Up Confirms Prognostic Impact of Pai-1 and Cathepsin D and L in Primary Breast Cancer

A. Krüger, N. Harbeck, F. Jänicke, 2000, The International journal of biological markers.

Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.

E. Lengyel, M. Schmitt, W. Kuhn, 2001, Gynecologic oncology.

Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.

E. Lengyel, M. Schmitt, W. Kuhn, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Y‐box factor YB‐1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI‐1

N. Harbeck, P. Dettmar, M. Schmitt, 2002, International journal of cancer.

Ovarian Prognostic Significance of Urokinase (upa) and Its Inhibitor Pai-1 for Survival in Advanced Ovarian Carcinoma Stage Figo Iiic

H. Höfler, N. Harbeck, P. Dettmar, 2022 .

Factors influencing survival after resection of pulmonary metastases from colorectal cancer

H. Präuer, U. Berger, H. Vogelsang, 2004, The British journal of surgery.

Invasion marker PAI‐1 remains a strong prognostic factor after long‐term follow‐up both for primary breast cancer and following first relapse

H. Höfler, N. Harbeck, K. Ulm, 1999, Breast Cancer Research and Treatment.

Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.

H. Höfler, A. Krüger, N. Harbeck, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc

H. Höfler, N. Harbeck, P. Dettmar, 1999, British Journal of Cancer.